Reckitt Extends Mucinex, Airborne Lines In Global Consumer Expansion
This article was originally published in The Tan Sheet
Executive Summary
The U.K. firm extends Mucinex outside the decongestant category to treating allergies, where the brand faces strong branded and private label competition. An Airborne supplement line extension and wider distribution of MegaRed omega-3 products also factor in the firm’s 2014 consumer health care plans.
You may also be interested in...
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.
Reckitt Reorganizes To Develop Health Care, Emerging Markets
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.